1-19 of 19
Wei Deng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5134: Biomarker concordance between matched primary and metastatic colorectal tumors

Yun Yang, Ying Xin, Jianning Song, Chao Jing, Baoyi Zhao, Depei Huang, Wei Deng
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5134.
DOI: https://doi.org/10.1158/1538-7445.AM2022-5134
Published: 15 June 2022
View article
Journal Articles

Abstract 5457: QLH11811, a selective 4th-generation EGFR inhibitor for osimertinib-resistant EGFR-mutant NSCLC

Shansong Zheng, Wei Deng, Qingmei Zheng, Yingying Yang, Na Li, Tan Pang, Xueying Feng, Simon Taylor, Lina Ma, Yaqiong Wu, Ziwei Zhao
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5457.
DOI: https://doi.org/10.1158/1538-7445.AM2022-5457
Published: 15 June 2022
View article
Journal Articles

Abstract 1469: TPX-0131, a potent inhibitor of wild type ALK and a broad spectrum of both single and compound ALK resistance mutations

Brion W. Murray, Dayong Zhai, Wei Deng, Evan Rogers, Xin Zhang, Jane Ung, Vivian Nguyen, Han Zhang, Maria Barrera, Ana Parra, Jessica Cowell, Dong Lee, Herve Aloysius
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1469.
DOI: https://doi.org/10.1158/1538-7445.AM2021-1469
Published: 01 July 2021
View article
Journal Articles

Abstract 1444: TPX-0022, a potent MET/SRC/CSF1R inhibitor that modulates the tumor immune microenvironment in preclinical models

Vikas K. Goel, Wei Deng, Dayong zhai, Nathan V. Lee, Ana Parra, Brion W. Murray
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1444.
DOI: https://doi.org/10.1158/1538-7445.AM2021-1444
Published: 01 July 2021
View article
Journal Articles

Abstract 1104: Repotrectinib increases effectiveness of MEK inhibitors in KRAS mutant cancer models

Nathan V. Lee, Wei Deng, Dayong Zhai, Laura Rodon, Ana Parra, Jessica Cowell, Afsheen Banisadr, Xin Zhang, Brion W. Murray
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1104.
DOI: https://doi.org/10.1158/1538-7445.AM2021-1104
Published: 01 July 2021
View article
Journal Articles

Abstract 1119: Molecular characteristics of repotrectinib that enable potent inhibition of TRK fusion proteins and broad mutant selectivity

Alexander Drilon, Dayong Zhai, Evan Rogers, Wei Deng, Xi Chen, Paul Sprengeler, Siegfried H. Reich, Brion W. Murray
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1119.
DOI: https://doi.org/10.1158/1538-7445.AM2021-1119
Published: 01 July 2021
View article
Journal Articles

Abstract 5226: TPX-0131: A next generation macrocyclic ALK inhibitor that overcomes ALK resistant mutations refractory to current approved ALK inhibitors

J. Jean Cui, Evan Rogers, Dayong Zhai, Wei Deng, Jane Ung, Vivian Nguyen, Han Zhang, Xin Zhang, Ana Parra, Maria Barrera, Dong Lee, Brion Murray
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5226.
DOI: https://doi.org/10.1158/1538-7445.AM2020-5226
Published: 15 August 2020
View article
Journal Articles

Abstract 1958: Repotrectinib increases effectiveness of KRAS-G12C inhibitors in KRAS-G12C mutant cancer models via simultaneous SRC/FAK/JAK2 inhibition

J. Jean Cui, Dayong Zhai, Wei Deng, Laura Rodon, Nathan Lee, Brion Murray
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1958.
DOI: https://doi.org/10.1158/1538-7445.AM2020-1958
Published: 15 August 2020
View article
Journal Articles

Abstract 1957: Repotrectinib increases effectiveness of MEK inhibitor trametinib in KRAS mutant cancer models via simultaneous SRC/FAK/JAK2 inhibition

Brion Murray, Wei Deng, Dayong Zhai, Laura Rodon, Nathan Lee, J. Jean Cui
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1957.
DOI: https://doi.org/10.1158/1538-7445.AM2020-1957
Published: 15 August 2020
View article
Journal Articles

Abstract 1319: Repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations

Wei Deng, Dayong Zhai, Xin Zhang, Dong Lee, Evan Rogers, Jeffrey Whitten, J. Jean Cui
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1319.
DOI: https://doi.org/10.1158/1538-7445.AM2019-1319
Published: 01 July 2019
View article
Journal Articles

Abstract 1325: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC inhibits tumor growth by promoting anti-tumor immune responses

Wei Deng, Dayong Zhai, Evan Rogers, Xin Zhang, Dong Lee, Jane Ung, Han Zhang, Jing Liu, Yuelie Lu, John Huang, Armin Graber, Zach Zimmerman, John Lim, Jeffrey Whitten, J. Jean Cui
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1325.
DOI: https://doi.org/10.1158/1538-7445.AM2019-1325
Published: 01 July 2019
View article
Journal Articles

Abstract 1321: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling

Dayong Zhai, Evan Rogers, Wei Deng, Xin Zhang, Dong Lee, Jane Ung, Han Zhang, Jing Liu, Yuelie Lu, John Huang, Armin Graber, Zach Zimmerman, John Lim, Jeffrey Whitten, J. Jean Cui
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1321.
DOI: https://doi.org/10.1158/1538-7445.AM2019-1321
Published: 01 July 2019
View article
Journal Articles

Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations

Alexander Drilon, Dayong Zhai, Wei Deng, Xin Zhang, Dong Lee, Evan Rogers, Jeffrey Whitten, Zhongdong Huang, Armin Graber, Juliet Liu, Shanna Stopatschinskaja, J. Jean Cui, Dong-Wan Kim, Byoung Chul Cho, Robert C. Doebele, Sai-Hong Ignatius Ou, Jeeyun Lee, Alice T. Shaw
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 442.
DOI: https://doi.org/10.1158/1538-7445.AM2019-442
Published: 01 July 2019
View article
Journal Articles

Abstract 4796: Ropotrectinib is a novel polypharmacology kinase inhibitor against WT and mutant ROS1, TRK and ALK

Wei Deng, Dayong Zhai, John Huang, Evan Rogers, Jeffrey Whitten, John Lim, Yishan Li, Jean Cui
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4796.
DOI: https://doi.org/10.1158/1538-7445.AM2018-4796
Published: 01 July 2018
View article
Journal Articles

Abstract 3161: TPX-0005, an ALK/ROS1/TRK inhibitor, overcomes multiple resistance mechanisms by targeting SRC/FAK signaling

Dayong Zhai, Wei Deng, John Huang, Evan Rogers, J. Jean Cui
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3161.
DOI: https://doi.org/10.1158/1538-7445.AM2017-3161
Published: 01 July 2017
View article
Journal Articles

Abstract 3168: Overcoming acquired drug resistance by TPX-0005, an ALK, ROS1 and pan-TRK inhibitor

Wei Deng, John Huang, Dayong Zhai, Evan Rogers, Jean Cui
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3168.
DOI: https://doi.org/10.1158/1538-7445.AM2017-3168
Published: 01 July 2017
View article
Journal Articles

Abstract 2132: The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors

Dayong Zhai, Wei Deng, Zhongdong Huang, Evan Rogers, J. Jean Cui.
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2132.
DOI: https://doi.org/10.1158/1538-7445.AM2016-2132
Published: 15 July 2016
View article
Journal Articles

Abstract 2133: Ending the endless acquired tyrosine kinase resistance mutations — Design of TPX-0005, a multi-target ALK/ROS1/TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R

J. Jean Cui, Evan Rogers, Dayong Zhai, Wei Deng, Zhongdong Huang, Jeffrey Whitten, Yishan Li
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2133.
DOI: https://doi.org/10.1158/1538-7445.AM2016-2133
Published: 15 July 2016
View article
Journal Articles

Abstract 1797: Preclinical evaluation of HM-018, a potent and selective JAK inhibitor in the treatment of myloproliferative disorders

Yongxin Ren, Wei Deng, Weihua Gu, Wuzhong Shen, Youjun Yu, Xiaoning Yang, Zhixiang Zhang, Shiming Fan, Yang Sai, Jian Wang, James Yan, Jia Li, Helen Zhao, Weiguo Qing, Weiguo Su
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 1797.
DOI: https://doi.org/10.1158/1538-7445.AM2012-1797
Published: 15 April 2012
View article